Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Satellos Bioscience ( (TSE:MSCL) ) has issued an update.
Satellos Bioscience reported full-year 2025 financial results on March 27, 2026 and highlighted major clinical and corporate milestones centered on its lead Duchenne muscular dystrophy drug SAT-3247. The Toronto-based biotech also detailed its cash position, increased R&D and G&A expenses, and a strengthened balance sheet that is expected to fund operations through 2027.
Clinically, Satellos advanced SAT-3247 into two Phase 2 trials in Duchenne, launching the pediatric BASECAMP study after global regulatory clearances and extending adult treatment in the TRAILHEAD study with data showing sustained or improved grip strength over 9 to 13 months. The company also presented biomarker and preclinical data supporting SAT-3247’s broader muscle-regeneration potential, uplisted to the Nasdaq Global Market, raised US$57.2 million in February 2026, and expanded its leadership and board to support its development and regulatory strategy.
The most recent analyst rating on (TSE:MSCL) stock is a Buy with a C$16.00 price target. To see the full list of analyst forecasts on Satellos Bioscience stock, see the TSE:MSCL Stock Forecast page.
Spark’s Take on MSCL Stock
According to Spark, TipRanks’ AI Analyst, MSCL is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue, large losses, and heavy cash burn with ongoing funding risk). Technicals are supportive due to a clear uptrend, but overbought signals temper that strength. Valuation is also constrained by negative earnings and no dividend support.
To see Spark’s full report on MSCL stock, click here.
More about Satellos Bioscience
Satellos Bioscience Inc. is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Its lead candidate, SAT-3247, is an oral small-molecule AAK1 inhibitor being developed as a dystrophin-independent, disease-modifying therapy for Duchenne muscular dystrophy and potentially other muscle disorders.
Average Trading Volume: 41,101
Technical Sentiment Signal: Sell
Current Market Cap: C$148.4M
Find detailed analytics on MSCL stock on TipRanks’ Stock Analysis page.